This is a StreetInsider.com Premium Only Page

CymaBay Therapeutics (CBAY) – StreetInsider.com Reports

Mar 22, 2024 09:56 AM Gilead (GILD) reduces 2024 earnings guidance after completing CymaBay takeover

Mar 22, 2024 09:18 AM Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY)

Mar 19, 2024 07:20 AM Jones Trading Downgrades CymaBay Therapeutic (CBAY) to Hold

Mar 11, 2024 08:24 AM Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer

Mar 4, 2024 08:04 AM CymaBay Therapeutics (CBAY) Announces EMA Acceptance of Marketing Authorization Application for Seladelpar

Feb 28, 2024 04:57 PM CymaBay Therapeutics (CBAY) Misses Q4 EPS by 4c

Feb 21, 2024 10:36 PM CymaBay Therapeutics (CBAY) Announces Publication of Positive Phase 3 RESPONSE Data of Seladelpar

Feb 20, 2024 08:59 AM Leerink Partners Downgrades CymaBay Therapeutic (CBAY) to Market Perform

Feb 14, 2024 04:06 AM LifeSci Capital Downgrades CymaBay Therapeutic (CBAY) to Market Perform

Feb 14, 2024 12:43 AM UBS Downgrades CymaBay Therapeutic (CBAY) to Neutral

Feb 13, 2024 03:53 PM Piper Sandler Downgrades CymaBay Therapeutic (CBAY) to Neutral

Feb 13, 2024 06:06 AM H.C. Wainwright Downgrades CymaBay Therapeutic (CBAY) to Neutral

Feb 13, 2024 05:37 AM BTIG Downgrades CymaBay Therapeutic (CBAY) to Neutral

Feb 12, 2024 06:03 PM Raymond James Downgrades CymaBay Therapeutic (CBAY) to Market Perform

Feb 12, 2024 05:32 PM Cantor Fitzgerald Downgrades CymaBay Therapeutic (CBAY) to Neutral

Feb 12, 2024 05:13 PM B.Riley Downgrades CymaBay Therapeutic (CBAY) to Neutral

Feb 12, 2024 04:23 PM Jones Trading Downgrades CymaBay Therapeutic (CBAY) to Hold

Feb 12, 2024 04:23 PM Jones Trading Downgrades CymaBay Therapeutic (CBAY) to Hold

Feb 12, 2024 11:21 AM Midday movers: Diamondback Energy rises, Arm goes parabolic

Feb 12, 2024 11:17 AM CymaBay Therapeutics (CBAY) option implied volatility after Gilead (GILD) acquires

Feb 12, 2024 10:36 AM William Blair Downgrades CymaBay Therapeutic (CBAY) to Market Perform

Feb 12, 2024 08:55 AM Gilead Sciences (GILD) to acquire CymaBay Therapeutics (CBAY) in $4.3bn cash deal

Feb 12, 2024 08:54 AM CymaBay Therapeutics (CBAY) call put ratio 28.50 calls to 1 put into Gilead (GILD) to acquire

Feb 12, 2024 08:45 AM CymaBay Therapeutics (CBAY) Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

Feb 12, 2024 08:42 AM Gilead to buy CymaBay for $4.3 billion in bets on liver disease treatment

Feb 12, 2024 08:34 AM CymaBay Therapeutics (CBAY) to Resume Trading at 9 a.m.

Feb 12, 2024 08:32 AM Gilead Sciences (GILD) to Acquire CymaBay Therapeutics (CBAY) for $32.50 Per Share, $4.3 Billion

Feb 12, 2024 08:25 AM CymaBay Therapeutics (CBAY) Halted, News Pending

Jan 31, 2024 07:39 AM CymaBay Therapeutic (CBAY) PT Raised to $26 at Oppenheimer

Jan 3, 2024 08:04 AM CymaBay (CBAY) Says New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in PBC in Phase 3 Post-Hoc Analysis of Seladelpar

Dec 19, 2023 08:13 AM CymaBay Therapeutic (CBAY) PT Raised to $29 at B.Riley

Dec 18, 2023 06:37 AM CymaBay Therapeutic (CBAY) PT Raised to $28 at H.C. Wainwright

Dec 18, 2023 04:55 AM CymaBay Therapeutic (CBAY) PT Raised to $26 at BTIG

Dec 15, 2023 08:00 AM CymaBay Therapeutics (CBAY) Submits NDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

Nov 8, 2023 06:42 AM CymaBay Therapeutic (CBAY) PT Raised to $24 at H.C. Wainwright

Nov 7, 2023 04:04 PM CymaBay Therapeutics (CBAY) Misses Q3 EPS by 3c

Nov 6, 2023 07:31 AM CymaBay Therapeutic (CBAY) PT Raised to $33 at Piper Sandler

Oct 23, 2023 08:09 AM CymaBay Therapeutics (CBAY) Announces Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or W

Oct 9, 2023 08:54 AM Piper Sandler highlights 12 biotech takeover targets as M&A 'about as conducive as we've seen'

Sep 21, 2023 08:02 AM CymaBay Therapeutics (CBAY) Initiates AFFIRM Phase 3b/4 Study of the Effect of Seladelpar

Sep 12, 2023 10:04 AM Increasing unusual put option volume: ACB CGC PCT CBAY ORCL SCO PLAY RTX TLRY EQNR

Sep 12, 2023 04:43 AM CymaBay Therapeutics (CBAY) Prices Upsized $225M Share and Warrant Offering at $17.13/sh

Sep 11, 2023 06:00 AM CymaBay Therapeutics (CBAY) Announces Proposed $150M Share and Warrant Offering

Sep 8, 2023 09:11 AM CymaBay Therapeutic (CBAY) PT Raised to $20 at Leerink Partners

Sep 8, 2023 08:06 AM CymaBay Therapeutic (CBAY) PT Raised to $22 at B.Riley

Sep 8, 2023 05:08 AM CymaBay Therapeutic (CBAY) PT Raised to $24 at BTIG

Sep 7, 2023 01:50 PM CymaBay Therapeutic (CBAY) PT Raised to $22 at Oppenheimer

Sep 7, 2023 09:47 AM Increasing unusual put option volume: DBI CBAY PLAY SWKS GLW HCP AEO DELL STX NANOS EH

Sep 7, 2023 07:02 AM CymaBay's (CBAY) Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis

Aug 14, 2023 09:44 AM CymaBay Therapeutic (CBAY) PT Raised to $21 at H.C. Wainwright